Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Picard Medical, Inc. ( (PMI) ) just unveiled an announcement.
On March 20, 2026, Picard Medical announced that its SynCardia unit will present new preclinical data on its next-generation Emperor Total Artificial Heart at the American College of Cardiology’s Annual Scientific Session in New Orleans, scheduled for March 28–30, 2026. The poster, to be presented on March 29 by engineering project manager Duffy Elmer, will detail early engineering and preclinical evaluation of a fully implantable, autoregulating electromechanical artificial heart system designed to maintain the proven hemodynamic performance of the existing SynCardia Total Artificial Heart.
Throughout the conference, SynCardia will also exhibit at booth 2554, where clinicians and industry participants can learn about the FDA-approved SynCardia Total Artificial Heart and its use as a bridge to transplant in advanced biventricular heart failure. The company’s presence at the event highlights its strategy to leverage its established artificial heart platform while showcasing the Emperor program as the next evolution in total artificial heart therapy, aimed at expanding treatment options and improving patient mobility and quality of life, thereby reinforcing its leadership in advanced heart failure solutions.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc. is the parent of Tucson-based SynCardia Systems, a leader in total artificial heart technology for patients with end-stage heart failure. SynCardia develops and commercializes the SynCardia Total Artificial Heart, the first artificial heart approved by both the U.S. FDA and Health Canada and currently the only commercially available artificial heart in the U.S. and Canada.
The SynCardia Total Artificial Heart is an implantable system that fully assumes the circulatory functions of a failing human heart and is widely used as a bridge to transplant for advanced biventricular heart failure. With more than 2,100 implants across 27 countries, it is the most widely used and extensively studied artificial heart platform globally, underscoring SynCardia’s entrenched position in the mechanical circulatory support market.
Average Trading Volume: 801,833
Technical Sentiment Signal: Strong Sell
See more data about PMI stock on TipRanks’ Stock Analysis page.